Literature DB >> 2306236

Regioselectivity and stereoselectivity in the metabolism of HMG-CoA reductase inhibitors.

K P Vyas1, P H Kari, S M Pitzenberger.   

Abstract

Biotransformation of three analogs of simvastatin, L-672,201, L-157,012 and L-672,220, by rat liver microsomes has been examined. These compounds differ from each other at the 6' position of the hexahydronaphthalene system. When 6'-substituents were in the alpha configuration, rat liver microsomes catalysed biotransformation primarily at the 6' position. Hydroxylation was stereoselective giving 6' beta-hydroxy derivatives as major metabolites. In contrast, when the 6'-substituent had a beta-configuration, metabolism at this site was blocked. Rates of metabolism (nmols/mg protein/min) also indicated that 6' beta-derivatives were poorer substrates than their 6' alpha-counterparts. The results indicate that cytochrome P-450 exhibits a high degree of regio- and stereoselectivity in the metabolism of HMG-CoA reductase inhibitors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2306236     DOI: 10.1016/0006-291x(90)90987-x

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

Review 1.  Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.

Authors:  H Lennernäs; G Fager
Journal:  Clin Pharmacokinet       Date:  1997-05       Impact factor: 6.447

Review 2.  Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia.

Authors:  G L Plosker; D McTavish
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

Review 3.  Clinical pharmacokinetics and practical applications of simvastatin.

Authors:  V F Mauro
Journal:  Clin Pharmacokinet       Date:  1993-03       Impact factor: 6.447

4.  Sex difference in metabolism of simvastatin by rat hepatic microsomes.

Authors:  M Ohtawa; N Uchiyama
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Jul-Sep       Impact factor: 2.441

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.